Glycation of recombinant human interferon-gamma (rhIFN-γ) 
Introduction
Human interferon-gamma (hIFN-γ) is extensively studied because of its multiple biologic activities including antiviral, antiproliferaitive, immunomodulating and gene regulating activities (29) . Because of this wide spectrum of biologic activities hIFN-γ is used as a medicine for treatment of many infectious and metabolic diseases. The clinical application of hIFN-γ, however, is limited by its structural instability resulting in reduction of biologic activity (11, 14) . Most of the hIFN-γ preparations used in medicine are recombinant proteins. We have previously patented a method for manufacturing of recombinant hIFN-γ (rhIFN-γ) in bacterial (Escherichia coli) cells (13) . Searching for the reasons for structural changes in rhIFN-γ we have recently shown that it is affected by the Maillard reaction (12) occurring in the producing bacterial cells (15) . The Maillard reaction called non-enzymatic glycosylation, known also as glycation, proceeds in several steps. The first one involves formation of early glycation products, called Amadori products, on account of the interaction of reducing sugars with amino compounds, including proteins. After a series of chemical rearrangements the Amadori products turn into toxic and immunogenic compounds named advanced glycation end products (AGEs). A key characteristic of AGEs is their ability to form intraand intermolecular covalent crosslinks that alter the structure and function of the target protein. For this reason AGEs are important pathogenetic mediators in diabetic complications (25) and contribute to aging as well (17) . In a previous study we have shown that rhIFN-γ isolated from E. coli is modified with AGEs and undergoes partial proteolysis and covalent aggregation resulting in a reduced biologic activity (15) . We were further interested in potential approaches for suppression of rhIFN-γ glycation at the stage of its production in the bacterial cells. The inhibition of glycation is a new avenue for prevention of diabetic complication and aging. In this regard many chemicals have been tested to date for anti-glycation activity and shown to interfere with different stages of the glycation process. Amongst them are acetylsalicylic acid (aspirin), aminoguanidine, arginine, thiamine (vitamin B 1 ), vitamin B 6 (pyridoxine, pyridoxal 5'-phosphate and pyridoxamine).
Acetylsalicylic acid (ASA) and vitamin B 6 (pyridoxal-5'-phosphate) are shown to act as modifiers of the free amino groups in proteins thus preventing their accessibility for the carbonyl groups in reducing sugars (6, 9, (22) (23) (24) . ASA (aspirin) has also demonstrated some capacity to decrease the level of AGEs (33) by chelating copper and other transition metal ions contributing to the production of reactive oxygen species, as well as by scavenging free carbonyls. Other glycation inhibitors like aminoguanidine compete with aldose and ketose sugars for their binding to the proteins. Apparently they affect more than one stage of the glycation process. The primary mechanism of glycation inhibition by aminoguanidine seems to be the interaction of the guanidine group with dicarbonyl intermediates such as methylglyoxal, glyoxal and 3-deoxyglucosone (3-DG) (27, 28) . Similar inhibitory mechanism has been proposed also for arginine (bearing guanidine functionality). Vitamin B 1 acts on the later stages of glycation supposedly by destroying the pre-formed AGE-crosslinks. It should be mentioned that it does not prevent their formation (1) .
One of the most extensively studied antiglycating agent is vitamin B 6 . It exists in vitamer forms (pyridoxine, pyridoxal and pyridoxamine), which are usually phosphoryated. The most active anti-glycating vitamin B 6 (18, 19) . The B 6 vitamer pyridoxine inhibits AGEs formation by blocking the oxidative degradation of Amadori products (31) . It removes also toxic carbonyl compound derived from glucose and lipids, and captures reactive oxygen and carbonyl intermediates that are involved in the formation of AGEs (21, 32) . In a recent study we have shown that some glycation inhibitors are effective in prevention of rhIFN-γ from glycation and structural changes (3) . In the present study we are particularly interested in the effect of glycation inhibitors on the biological activity of rhIFN-γ.
Material and Methods

Preparation of rhIFN-γ samples
The E. coli strain LE392 was transformed with a plasmid carrying the hIFN-γ gene cloned under a strong phage promoter and a consensus E. coli ribosome binding site. Transformed cells were cultured overnight at 37°C in Luria-Bertani medium containing 12 μg/ml tetracycline and each of the glycation inhibitors at the concentrations indicated in Table 1 below. The overnight cultures were reinoculated in fresh LB media with the same supplements and cultivated to an optical density of 0.7 OD 590 . Control cells were grown under the same conditions in the absence of glycation inhibitors. Cells corresponding to 6 OD 590 were collected by centrifugation, resuspended in 1 ml 0.14 M NaCl, 10 mM Tris (pH 8.0), 0.1 mM phenylmethylsulfonyl fluoride and disrupted by sonication. After centrifugation at 12 000 rpm/min for 15 min at 4°C the clear cell lysates containing the soluble fraction of rhIFN-γ were sterilized by filtration through a 0.22 μm filter and used in the antiproliferative assay.
Protein concentration measurement
The concentration of the total protein in the clear cell lysates was determined by the method of Bradford (5), whereas the concentration of rhIFN-γ was measured by means of direct enzyme-linked immunosorbent assay (ELISA). Briefly, ELISA 96-well microtiter plates were coated with 50 µl/well sample proteins diluted in PBS to a final concentration of 27 μg/ml. In parallel, 50 µl/well of purified rhIFN-γ to serve as a standard was added to the plates in duplicate serial dilutions ranging from 1 μg/ml to 0.03 μg/ml. After overnight incubation at 4°C the plate was washed three times for 5 min with 0.5% Tween 20 in PBS and wells were blocked with 200 µl/well 2% BSA in PBS for 1 hour at 37°C. After washing as above, 50 µl/well monoclonal anti-hIFN-γ antibody diluted in 1% BSA/PBS was added and the reaction was carried out for 2 hours at 37°C. After three washing steps, an anti-mouse IgG conjugated with horseradish peroxidase diluted 1:6000 in 1% BSA/PBS was added at 50 µl/well. The plate was incubated for 1 hour at 37°C and then washed three times for 10 min. Color reaction was performed with 50 µl/well o-phenylenediamine dissolved at 5 mg/ml in 0.2 M citrate buffer (pH 5.2) and 10% H 2 O 2 for 20 min in the dark. The reaction was stopped with 50 µl/well 10% H 2 SO 4 , and the absorption at 492 nm was read in an ELISA plate reader.
Antiproliferative assay
Biologic (antiproliferative) activity of rhIFN-γ was measured by a modified kynurenine bioassay (4). In 96-well plates, aliquots of 100 µl/well clear cell lysates containing rhIFN-γ were serially diluted with minimum essential Eagle medium (MEM) supplemented with fetal bovine serum (FBS). The wells were seeded with 50 μl WISH cell suspension (3x10 5 cells/ml) in MEM Eagle medium supplemented with 10% FBS and 50 μl 400 μg/ml of L-tryptophan. The plate was incubated for 72 hours at 37°C. After incubation, 50 μl of cell supernatants were transferred to a plate containing 50 μl distilled water per well. Then, 100 μl of freshly prepared Ehrlich's reagent were added and 10 min later the absorbance at 492 nm was measured in a microplate reader. Blank controls, containing MEM medium, L-tryptophan and WISH cells that were not treated with rhIFN-γ, were processed in the same way as the samples. The measured values were converted into international units using a standard calibration curve prepared with purified rhIFN-γ (5x10 7 IU/mg).
Results and Discussion
Interferons modulate the immune system response to viruses, bacteria, cancer, and other foreign substances that invade the body. Human IFN-γ is approved for treatment of chronic granulomatous disease and severe malignant osteopetrosis. Most of the commercially available human interferons are manufactured by the recombinant DNA technology in either eukaryotic or bacterial host cells. We have previously shown that the Maillard reaction (glycation) does take place not only in eukaryotes but also in E. coli, the "workhorse" of the current biotechnology. We further demonstrated that glycation affects both E. coli own and recombinant (rhIFN-γ) proteins (14, 15) and also E. coli chromosomal DNA (16 proteolysis and protein aggregation, including formation of covalent dimers and multimers. These structural alterations cause loss of biologic activity of rhIFN-γ during storage even in a frozen or lyophilized form. In order to prevent (or at least minimize) the effects of glycation we have studied the effect of several chemical compounds with antiglycation potential on the biologic activity of rhIFN-γ. The compounds listed in Table 1 were applied at non-toxic for the producing cells concentrations. In preliminary studies we have shown that at these concentrations they do not impede bacterial growth or cause a significant rise in the E. coli spontaneous mutation rate (Mironova and co-workers, unpublished data).
Glycation inhibitors were added at the indicated concentrations to the culture medium of E. coli producing rhIFN-γ and clear cell lysates were prepared as described in the Methods section. In order to avoid laborious work, associated with rhIFN-γ purification, the biologic (antiproliferative) activity was tested directly on cell lysates. Human rIFN-γ concentration was measured by ELISA and its activity was related to a milligram of protein.
The results from this study are presented in Table  2 . Table 2 demonstrates that the total protein yield in E. coli cells grown in the presence of any of the seven glycation inhibitors was lower as compared to that of the untreated cells. The compound suppressing most strongly the yield of both total E. coli protein and rhIFN-γ was aminoguanidine. The yield of total E. coli protein obtained from cells cultivated with glycation inhibitors varied between 37.2% (aminoguanidine) and 72.4% (argininge) compared to the control cells (100%). The yield of rhIFN-γ followed nearly the same trend except for the pyridoxamine (reducing the yield of rhIFN-γ more extensively rather than the total bacterial protein).
Biological activity of rhIFN-γ was measured by a modified kynurenine method (4) based on its antiproliferative activity. Interacting with WISH cell receptors, rhIFN-γ induces the expression of indoleamine 2,3-dioxygenase (IDO) converting tryptophan into kynurenine. Thereby, the concentration of kynurenine is directly proportional to the concentration of rhIFN-γ used for induction. The reaction is easily monitored by a colorimetric assay of the reaction product of kynurenine with Ehrlich's reagent absorbing at 490 nm. We used the kynurenine bioassay to follow the change in the biologic activity of rhIFN-γ over time. The first test was performed immediately after isolation of the cell lysates, whereas all subsequent analyses were done at nearly one month intervals. In-between samples were stored at -20°C. The results are presented in Table 3 .
As seen in Table 3 , at all time points the rhIFN-γ samples isolated from control cells (cultured in the absence of glycation inhibitors) showed lower biologic activity. In other words, all glycation inhibitors exerted a favorable effect on the rhIFN-γ biologic activity. At the time of isolation rhIFN-γ obtained from cells grown in the presence of aminoguanidine exhibited highest biologic activity (1.2x10 7 IU/mg). It should be mentioned that this activity is close to that of the standard rhIFN-γ (5x10 7 IU/mg) produced by the method patented by Marekov et al. (13) . The high activity of rhIFN-γ from aminoguanidine treated cells, however, was poorly sustained over time. It dropped nearly two orders of magnitude after three months of storage. Experimental evidence indicates that amino- (20, 26) . Despite this evidence aminoguanidine (Pimagedine) has been introduced into clinical trials for prevention of diabetic nephropathy (2) but withdrawn later in the crucial Phase III because of neurotoxicity (10) . Due to its high carbonyl trapping activity, aminoguanidine is a perfect glycation inhibitor in vitro, however, because of its extremely high affinity to life essential carbonyls like pyridoxal 5'-phosphate, it is not applicable in vivo. Thus, the inhibition of glycation in living systems appears to be a serious challenge to be faced by the scientists working today in the field of the Maillard reaction. Although the arginine resembles aminoguanidine (it also contains a guanidyl group), in our study it proved to be a worse inhibitor of rhIFN-γ glycation. At the time of isolation rhIFN-γ from arginine treated cells showed two orders of magnitude lower biologic activity (7.9x10 5 IU/mg) in comparison with that of rhIFN-γ obtained from cells cultivated in the presence of aminoguanidine (1.2x10 7 IU/mg). This activity gradually decreased over time and after three months of storage approached the level of rhIFN-γ isolated from aminoguanidine treated cells.
The three B 6 vitamers also exerted diverse effects on rhIFN-γ activity. The highest initial biologic activity (4.5x10 6 IU/mg) was observed with pyridoxine, followed by aminoguanidine (1.2x10 7 IU/mg). This activity was stable over two months and dropped nearly ten times during the third month of storage. When rhIFN-γ was isolated from pyridoxamine treated cells, it demonstrated high initial activity, but it decreased rapidly compared to the activity of rhIFN-γ obtained from pyridoxine treated cells. The worst inhibitor among the B 6 vitamers was the pyridoxal-5'-phosphate. The biologic activity of fresh rhIFN-γ preparations isolated from pyridoxal-5'-phosphate treated cells was 4.3x10 5 IU/mg, i.e. about one order of magnitude lower than that of the rhIFN-γ obtained from pyridoxine treated cells (4.5x10 6 IU/mg). The negative impact of pyridoxal-5'-phophate on rhIFN-γ biologic activity might be explained by its aldehyde functionality. Experiments with lens crystallins led to the conclusion that pyridoxal-5'-phophate forms Schiff bases with protein amino groups (7, 8) . Therefore, we assume that the lowering effect of pyridoxal-5'-phophate on rhIFN-γ activity is related with rhIFN-γ "vitamination". The other vitamin used in our study, vitamin B 1 (thiamine) exerted similar effect on rhIFN-γ biologic activity, i.e. low starting activity slowly dropping with time. It is worth mentioning that at the third month of storage the biologic activity of rhIFN-γ obtained from cells treated with any of the glycation inhibitors was still greater than that of fresh rhIFN-γ preparations isolated form control (untreated) cells.
The most favorable effect on rhIFN-γ activity in our study was obtained with aspirin. Although the rhIFN-γ preparations obtained from aspirin treated cells had lower starting activity (2.03x10 6 IU/mg) compared to the aminoguanidine (2.1x10 7 IU/mg) and pyridoxine (4.5x10 6 IU/mg) treated cells, this activity was stably maintained over time. It dropped only two times for three months of storage. At the end of the testing period, the rhIFN-γ obtained from aspirin treated cells demonstrated the highest biologic activity (1.01x10 6 IU/mg), five to ten times higher than that of rhIFN-γ isolated from cells treated with any one of the other six inhibitors. These results confirm our previous data showing that aspirin protects rhIFN-γ from structural damage and protects its biological activity better than vitamin B 1 . After one month of storage at 4°C, rhIFN-γ isolated from aspirin treated cells contained a negligible amount of degradation products and covalent dimers, and its biologic activity remained almost unchanged (3) .
Conclusions
All glycation inhibitors tested in this study demonstrated favorable effect on rhIFN-γ biologic activity, which fully justifies their use during E. coli cultivation. Aspirin was the best protector of both biologic activity and physicochemical stability of rhIFN-γ in solution and should be further explored in the large scale production of rhIFN-γ.
